12 Jun Adagrasib (KRAS inhibitor) in Non–Small-Cell Lung Cancer Harboring a KRASG12C Mutation
In patients with KRASG12C-mutated NSCLC previously treated with platinum-based chemotherapy and checkpoint inhibitor therapy, adagrasib showed an objective response of 42.9%. Tumor shrinkage of any magnitude was observed in 79.5% patients (A). Intracranial tumor shrinkage was also seen (B). The median duration of response was 8.5 months (95% CI 6.2 to 13.8), the median PFS was 6.5 months (95% CI, 4.7 to 8.4) and the median overall survival was 12.6 months (95% CI, 9.2 to 19.2). The results were similar to sotorasib.
(Ref: Jänne PA et al. N Engl J Med. June 3, 2022)